Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Interest & Investment Income (2016 - 2025)

Lineage Cell Therapeutics' Interest & Investment Income history spans 9 years, with the latest figure at $393000.0 for Q4 2025.

  • For Q4 2025, Interest & Investment Income changed 0.0% year-over-year to $393000.0; the TTM value through Dec 2025 reached $1.7 million, down 1.4%, while the annual FY2025 figure was $1.7 million, 1.4% down from the prior year.
  • Interest & Investment Income reached $393000.0 in Q4 2025 per LCTX's latest filing, up from $366000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $478000.0 in Q1 2025 to a low of $2000.0 in Q1 2021.
  • Average Interest & Investment Income over 4 years is $387461.5, with a median of $404000.0 recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: tumbled 99.51% in 2021, then rose 21.2% in 2024.
  • A 4-year view of Interest & Investment Income shows it stood at $2000.0 in 2021, then surged by 20100.0% to $404000.0 in 2023, then dropped by 2.72% to $393000.0 in 2024, then changed by 0.0% to $393000.0 in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Interest & Investment Income are $393000.0 (Q4 2025), $366000.0 (Q3 2025), and $454000.0 (Q2 2025).